Persistent low prevalence of hepatitis B vaccination among people with HIV: Time for a change?

Angie Garcia, Karen J. Vigil, Barbara Taylor, Onkar Kshirsagar, Mae Thamer, Mamta K. Jain

Research output: Contribution to journalArticlepeer-review


Hepatitis B virus (HBV) infection is one of the leading causes of hepatocellular carcinoma and mortality among people living with HIV (PLWH). HBV vaccination provides protection from infection; however, vaccination rates are low. We conducted a retrospective analysis at three HIV centres in Texas to determine the proportion of PLWH who received the recommended 3 doses of hepatitis B vaccine within 1 year. Factors associated with vaccination completion were explored. In our sample of three sites in a state with high HIV transmission and high rates of liver disease from 2011 to 2021, showed low rates of hepatitis B vaccination. Among eligible PLWH, only 9% completed the 3-dose hepatitis B vaccine series in 1 year. There is an urgent need to improve HBV vaccination to reach 2030 target for hepatitis B elimination.

Original languageEnglish (US)
Pages (from-to)790-792
Number of pages3
JournalJournal of Viral Hepatitis
Issue number10
StatePublished - Oct 2023


  • HIV
  • hepatitis B vaccination
  • practice patterns

ASJC Scopus subject areas

  • Infectious Diseases
  • Virology
  • Hepatology


Dive into the research topics of 'Persistent low prevalence of hepatitis B vaccination among people with HIV: Time for a change?'. Together they form a unique fingerprint.

Cite this